Albert DaCosta has been the CEO of Paragon 28 since the company's inception in 2012. He holds a B.S. in Chemical Engineering from the University of Florida, which gives him a solid technical background in the medical device industry. With...

Albert DaCosta has been the CEO of Paragon 28 since the company's inception in 2012. He holds a B.S. in Chemical Engineering from the University of Florida, which gives him a solid technical background in the medical device industry. With over 18 years of experience specifically focusing on foot and ankle products, his knowledge is practical and extensive. DaCosta has played a key role in the company’s journey and has a significant stake in its growth, holding 11,661,097 shares of common stock, that accounted for about 14.05% of the company's outstanding shares as of March 2023. In 2023, he received a total compensation package of $3,232,420, which included a salary of $700,769 and a substantial bonus driven by performance metrics. Interestingly, his net worth fluctuated dramatically over the past couple of years; during peak months in late 2022, his holdings were valued at around $136 million, but this dropped to around $54 million by early 2024. DaCosta’s practical experience in the field, combined with his business insight gained from years in leadership, positions him as a significant figure in the orthopedic sector. His leadership style emphasizes aligning executive compensation with the company’s performance, demonstrating his commitment to shareholder interests.